Neurobiology of Aging
Volume 29, Issue 10 , Pages 1485-1493 , October 2008

αv integrins mediate beta-amyloid induced inhibition of long-term potentiation

  • Qinwen Wang

      Affiliations

    • Department of Physiology, Trinity College, Dublin 2, Ireland
    • These authors contributed equally to the work.
    • Present address: Department of Physiology and Pharmacology, The Medical School, Ningbo University, Ningbo, China.
    • ,
  • Igor Klyubin

      Affiliations

    • Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    • These authors contributed equally to the work.
    • ,
  • Sarah Wright

      Affiliations

    • Elan Pharmaceuticals, 1000 Gateway Boulevard, South San Francisco, CA 94080, USA
    • ,
  • Irene Griswold-Prenner

      Affiliations

    • Elan Pharmaceuticals, 1000 Gateway Boulevard, South San Francisco, CA 94080, USA
    • ,
  • Michael J. Rowan

      Affiliations

    • Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
    • These authors contributed equally to the work.
    • ,
  • Roger Anwyl

      Affiliations

    • Department of Physiology, Trinity College, Dublin 2, Ireland
    • These authors contributed equally to the work.
    • Corresponding Author InformationCorresponding author. Tel.: +353 18961624.

Received 12 January 2007 ,Revised 13 March 2007 ,Accepted 17 March 2007.

References 

  1. Anderson JL, Head SI, Morley JW . Synaptic plasticity in the dy2J mouse model of laminin (2-deficient congenital muscular dystrophy.. Brain Res. 2005;1042:23–28
  2. Anderson KI, Ferreira A. α1 Integrin activation: a link between β-amyloid deposition and neuronal death in aging hippocampal neurons. J. Neurosci. Res. 2004;75:688–697
  3. Bahr BA, Staubli U, Xiao P, Chun D, Ji Z-X, Esteban ET, et al. Pharmacological studies and the characterization of a candidate matrix receptor. J. Neurosci. 1997;17:1320–1329
  4. Berg L, McKeel DW, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch. Neurol. 1993;50:349–358
  5. Chan C-S, Weeber EJ, Kurup S, Sweatt DJ, Davis RL. Integrin requirement for hippocampal synaptic plasticity and spatial memory. J. Neurosci. 2003;23:7107–7116
  6. Chang HP, Lindbeg FP, Wang HL, Huang AM, Lee EHY. Impaired memory retention and decreased long-term potentiation in integrin-associated protein-deficient mice. Learn. Memory. 1999;6:448–457
  7. Chun D, Gall CM, Bi X, Lynch G . Evidence that integrins contribute to multiple stages in the consolidation of long-term potentiation. Neuroscience. 2001;105:815–829
  8. Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 1997;8:3213–3217
  9. Dahlgren KN, Manelli AM, Stine WB, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002;277:32046–32053
  10. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci. 1987;78:151–164
  11. Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006;26:6011–6018
  12. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin A potent platelet aggregation inhibitor from the venom of the viper Echis carinatus. J. Biol. Chem. 1988;263:19827–19832
  13. Grotewiel MS, Beck CD, Wu CF, Greenspan RJ. Integrin-mediated short-term memory in Drosophila. Nature. 1998;18:7847–7855
  14. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  15. Humpries MJ. Integrin structure. Biochem. Soc. Trans. 2000;28:311–339
  16. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, et al. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 2004;19:2839–2846
  17. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid α protein immunotherapy neutralizes Aα oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 2005;11:556–561
  18. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar β-amyloid through a β1 integrin-dependent mechanism. J. Neurosci. 2004;24:9838–9846
  19. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005;25:8240–8249
  20. Kramer EA, Bernard JA, Gall CM, Lynch G. Alpha 3 integrin receptors contribute to the consolidation of long-term potentiation. Neuroscience. 2002;110:29–39
  21. Kramer EA, Lin B, Rex CS, Gall CM, Lynch G. Integrin-driven actin polymerisation consolidates long-term potentiation. PNAS. 2006;103:5579–5584
  22. Kumar CC, Nie H, Rogers CP, Malkowski M, Maxwell E, Catino JJ, et al. Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. J. Pharmacol. Exp. Ther. 1997;283:843–853
  23. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. 1998;95:6448–6453
  24. Lin B, Arai AC, Lynch G, Gall CM. Integrins regulate NMDAR receptor-mediated synaptic currents. J. Neurophysiol. 2003;89:2874–2878
  25. Morla A, Zhang Z, Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature. 1994;367:193–196
  26. Nishimura SL, Boylen KP, Einheber S, Milner TA, Ramos DM, Pytela R. Synaptic and glial localization of the integrin αvβ8 in mouse and rat brain.. Brain Res. 1998;791:271–282
  27. Pinkstaff JK, Detterich J, Lynch G, Gall C. Integrin subunit gene expression is regionally differentiated in adult brain. J. Neurosci. 1999;19:1541–1556
  28. Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus.. Brain Res. 2003;968:263–272
  29. Rosenmund C, Westbrook GL. Calcium-induced actin depolymerization reduces NMDA channel activity. Neuron. 1993;10:805–814
  30. Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL. Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci. Lett. 1995;184:25–28
  31. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789–791
  32. Sheppard D. Roles of αv integrins in vascular biology and pulmonary pathology. Curr. Opin. Cell Biol. 2004;16:552–557
  33. Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, Luk HN. Inhibition of angiogenesis in itro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha (v) beta3 integrin monoclonal antibody. Biochim. Biophys. Acta. 1997;1336:445–454
  34. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2002;8:595–598
  35. Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging. 2001;22:427–434
  36. Staubli U, Vanderklish PW, Lynch G. An inhibitor of integrin receptor blocks LTP. Behav. Neural. Biol. 1990;53:1–5
  37. Teter B, Ashford JW. Neuroplasticity in Alzheimer's disease. J. Neurosci. Res. 2002;70:402–437
  38. Van Waes C, Enamorado-Ayala I, Hecht D, Sulica L, Chen Z, Batt DG, et al. Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8. Int. J. Oncol. 2000;16:1189–1195
  39. Verdier Y, Zarandi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 2004;10:229–248
  40. Vitolo OV, Sant’Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling.. Proc. Natl. Acad. Sci. U.S.A. 2002;99:13217–13221
  41. Walsh DM, Klyubuin I, Fadeeva J, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of the Alzheimer amyloid (-protein potently inhibit long-term potentiation in vivo. Nature. 2002;416:535–539
  42. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 2004;24:3370–3378
  43. Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 2004;24:6049–6056
  44. Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur. J. Neurosci. 2005;22:2827–2832
  45. Wright S, Malinin NL, Powell KA, Yednock T, Rydel RE, Griswold-Prenner I. Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol. Aging. 2007;28:226–237

PII: S0197-4580(07)00128-5

doi: 10.1016/j.neurobiolaging.2007.03.018

Neurobiology of Aging
Volume 29, Issue 10 , Pages 1485-1493 , October 2008

Article Tools

* Image Usage & Resolution